
CAS 1428327-31-4
:Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
6 prodotti.
N-((4-(4-Phenylpiperazin-1-Yl)Tetrahydro-2H-Pyran-4-Yl)Methyl)-2-(Phenylthio)Nicotinamide
CAS:N-((4-(4-Phenylpiperazin-1-Yl)Tetrahydro-2H-Pyran-4-Yl)Methyl)-2-(Phenylthio)NicotinamidePurezza:99%Peso molecolare:488.64g/molJNJ-47965567
CAS:JNJ-47965567 (JNJ-479655) is a selective antagonist of the purinergic receptor P2X subtype 7 (P2X7), a ligand-gated ion channel(with pKis of 7.9 and 8.7 forFormula:C28H32N4O2SPurezza:99.11%Colore e forma:SolidPeso molecolare:488.64N-((4-(4-PHENYLPIPERAZIN-1-YL)TETRAHYDRO-2H-PYRAN-4-YL)METHYL)-2-(PHENYLTHIO)NICOTINAMIDE
CAS:Purezza:98%Peso molecolare:488.6499939JNJ-47965567
CAS:<p>JNJ-47965567 is a selective P2X7 receptor antagonist, which is derived from a rigorous screening of chemical libraries to target purinergic signaling pathways. Its mode of action involves competitive inhibition of the P2X7 receptor, a ligand-gated ion channel activated by extracellular ATP. This receptor is predominantly expressed in immune cells and is implicated in the release of pro-inflammatory cytokines.The primary applications of JNJ-47965567 lie in its potential therapeutic role in conditions where excessive inflammation is a contributing factor. Specifically, it is studied for its ability to modulate immune responses, with implications in autoimmune diseases, neurodegenerative disorders, and chronic pain. The specificity and efficacy of JNJ-47965567 as an antagonist allow it to serve as a valuable tool in elucidating P2X7 receptor function and its involvement in pathological processes. Research involving JNJ-47965567 continues to probe its pharmacodynamics and possible integration into therapeutic strategies targeting inflammation-driven diseases.</p>Formula:C28H32N4O2SPurezza:Min. 95%Peso molecolare:488.64 g/mol




